Spoken Alpha
VCYT
VERACYTE, INC.
Overview
Veracyte provides molecular diagnostic tests that help clinicians make treatment decisions for cancer patients. The company offers laboratory-developed tests in the U.S. through CLIA-certified labs for prostate, thyroid, bladder, and breast cancers, and distributes in vitro diagnostic tests internationally.
VERACYTE, INC is a Healthcare company operating in Diagnostics & Research with a $4.02B market cap.
Most recent reported earnings: Q3 FY2026 (Nov 2, 2026).
22 earnings calls indexed on Spoken Alpha.
Behavioral analysis
Management language signature
Disclosures
Investor Relations
Transcripts
Recent earnings calls
Most recent calls indexed for this ticker. Open any call to drill into prepared remarks and Q&A.
- Q2 FY2026Earnings2026-07-3013 Q&A exchanges
- Q1 FY2026Earnings2026-05-0510 Q&A exchanges
- Q4 FY2025Earnings2026-02-2519 Q&A exchanges
- Q3 FY2025Earnings2025-11-0414 Q&A exchanges
- Q2 FY2025Earnings2025-08-0714 Q&A exchanges
- Q1 FY2025Earnings2025-05-0827 Q&A exchanges
- Q4 FY2024Earnings2025-02-2421 Q&A exchanges
- Q3 FY2024Earnings2024-11-0627 Q&A exchanges
- Q2 FY2024Earnings2024-08-0618 Q&A exchanges
- Q1 FY2024Earnings2024-05-0717 Q&A exchanges
- Q4 FY2023Earnings2024-02-2225 Q&A exchanges
- Q3 FY2023Earnings2023-11-0724 Q&A exchanges
- Q2 FY2023Earnings2023-08-0814 Q&A exchanges
- Q1 FY2023Earnings2023-05-0431 Q&A exchanges
- Q4 FY2022Earnings2023-02-2328 Q&A exchanges
- Q3 FY2022Earnings2022-11-0219 Q&A exchanges
- Q2 FY2022Earnings2022-08-0219 Q&A exchanges
- Q1 FY2022Earnings2022-05-0323 Q&A exchanges
- Q4 FY2021Earnings2022-02-2825 Q&A exchanges
- Q3 FY2021Earnings2021-11-0924 Q&A exchanges
- Q2 FY2021Earnings2021-07-2926 Q&A exchanges
- Q1 FY2021Earnings2021-05-1015 Q&A exchanges
History
Earnings history
- Q3 FY20262026-11-02EPS— vs $0.28—Rev— vs ——EODHD
- Q2 FY20262026-07-29EPS$0.37 vs $0.29+27.6%Rev$150.3M vs ——EODHD
- Q1 FY20262026-05-04EPS$0.52 vs $0.33+57.6%Rev$139.1M vs ——EODHD
- Q4 FY20252026-02-24EPS$0.53 vs $0.39+35.9%Rev$140.6M vs ——EODHD
- Q3 FY20252025-11-03EPS$0.51 vs $0.32+59.4%Rev$131.9M vs ——EODHD
- Q2 FY20252025-08-05EPS$0.44 vs $0.30+46.7%Rev$130.2M vs ——EODHD
- Q1 FY20252025-05-06EPS$0.31 vs $0.20+55.0%Rev$114.5M vs ——EODHD
- Q4 FY20242025-02-19EPS$0.36 vs $0.26+40.0%Rev$118.6M vs ——EODHD
- Q3 FY20242024-11-05EPS$0.33 vs $0.17+94.1%Rev$115.9M vs ——EODHD
- Q2 FY20242024-08-05EPS$0.30 vs $-0.01+100.0%Rev$114.4M vs ——EODHD
- Q1 FY20242024-05-06EPS$0.04 vs $-0.10+100.0%Rev$96.8M vs ——EODHD
- Q4 FY20232024-02-21EPS$-0.39 vs $-0.09-100.0%Rev$98.2M vs ——EODHD
- Q3 FY20232023-11-06EPS$-0.41 vs $-0.13-100.0%Rev$90.1M vs ——EODHD
- Q2 FY20232023-08-07EPS$-0.12 vs $-0.14+14.3%Rev$90.3M vs ——EODHD
- Q1 FY20232023-05-03EPS$-0.11 vs $-0.110.0%Rev$82.4M vs ——EODHD
- Q4 FY20222023-02-21EPS$-0.05 vs $-0.15+66.7%Rev$80.3M vs ——EODHD
- Q3 FY20222022-11-01EPS$-0.12 vs $-0.23+47.8%Rev$75.6M vs ——EODHD
- Q2 FY20222022-08-01EPS$-0.13 vs $-0.22+40.9%Rev$72.9M vs ——EODHD
- Q1 FY20222022-05-02EPS$-0.20 vs $-0.23+13.0%Rev$67.8M vs ——EODHD
- Q4 FY20212022-02-27EPS$-0.15 vs $-0.16+6.3%Rev$67.3M vs ——EODHD
| Period | Reported | EPS actual | EPS consensus | EPS surprise | Revenue actual | Revenue consensus | Rev. surprise | Source |
|---|---|---|---|---|---|---|---|---|
| Q3 FY2026 | 2026-11-02 | — | $0.28 | — | — | — | — | EODHD |
| Q2 FY2026 | 2026-07-29 | $0.37 | $0.29 | +27.6% | $150.3M | — | — | EODHD |
| Q1 FY2026 | 2026-05-04 | $0.52 | $0.33 | +57.6% | $139.1M | — | — | EODHD |
| Q4 FY2025 | 2026-02-24 | $0.53 | $0.39 | +35.9% | $140.6M | — | — | EODHD |
| Q3 FY2025 | 2025-11-03 | $0.51 | $0.32 | +59.4% | $131.9M | — | — | EODHD |
| Q2 FY2025 | 2025-08-05 | $0.44 | $0.30 | +46.7% | $130.2M | — | — | EODHD |
| Q1 FY2025 | 2025-05-06 | $0.31 | $0.20 | +55.0% | $114.5M | — | — | EODHD |
| Q4 FY2024 | 2025-02-19 | $0.36 | $0.26 | +40.0% | $118.6M | — | — | EODHD |
| Q3 FY2024 | 2024-11-05 | $0.33 | $0.17 | +94.1% | $115.9M | — | — | EODHD |
| Q2 FY2024 | 2024-08-05 | $0.30 | $-0.01 | +100.0% | $114.4M | — | — | EODHD |
| Q1 FY2024 | 2024-05-06 | $0.04 | $-0.10 | +100.0% | $96.8M | — | — | EODHD |
| Q4 FY2023 | 2024-02-21 | $-0.39 | $-0.09 | -100.0% | $98.2M | — | — | EODHD |
| Q3 FY2023 | 2023-11-06 | $-0.41 | $-0.13 | -100.0% | $90.1M | — | — | EODHD |
| Q2 FY2023 | 2023-08-07 | $-0.12 | $-0.14 | +14.3% | $90.3M | — | — | EODHD |
| Q1 FY2023 | 2023-05-03 | $-0.11 | $-0.11 | 0.0% | $82.4M | — | — | EODHD |
| Q4 FY2022 | 2023-02-21 | $-0.05 | $-0.15 | +66.7% | $80.3M | — | — | EODHD |
| Q3 FY2022 | 2022-11-01 | $-0.12 | $-0.23 | +47.8% | $75.6M | — | — | EODHD |
| Q2 FY2022 | 2022-08-01 | $-0.13 | $-0.22 | +40.9% | $72.9M | — | — | EODHD |
| Q1 FY2022 | 2022-05-02 | $-0.20 | $-0.23 | +13.0% | $67.8M | — | — | EODHD |
| Q4 FY2021 | 2022-02-27 | $-0.15 | $-0.16 | +6.3% | $67.3M | — | — | EODHD |
Source: EODHD. VCYT reported actuals as published; sparse fields render as —.
Top executives
Executives who appear on this company's earnings calls in our corpus, with role and tenure sourced from SEC filings. Click any name for the full role timeline and call appearance history. Per-executive behavioral deviation metrics are available to research subscribers.
- Marc StapleyCEO5 yr 5 mo22 callsCurrent
- Rebecca ChambersCFO5 yr 4 mo21 callsCurrent
- John LeiteChief Commercial Officer-CLIA3 yr 2 mo4 callsCurrent
- Jonathan WygantVP, Chief Accounting Officer4 yr 8 mono recorded callsCurrent
- Annie McGuireEVP, General Counsel5 mono recorded callsCurrent
- Kevin Richard HaasChief Dev and Tech Officer8 mono recorded callsCurrent
Peers
Other companies in Healthcare
Sector peers tracked by Spoken Alpha. Each links to the same machine-readable IR surface — earnings calls, executives, and accountability scores.
API
For developers and AI agents
The same data on this page is available as a machine-readable feed via the Spoken Alpha API. One call returns the IR URL, recent transcripts, and accountability scores for VCYT.
$ curl https://api.spokenalpha.com/v1/companies/VCYTFAQ
Frequently asked about VCYT
Where can I find VERACYTE, INC.'s (VCYT) earnings call transcripts?
Spoken Alpha indexes VCYT's earnings call transcripts at https://spokenalpha.com/companies/VCYT. Each call links to attributed speakers and parsed analyst Q&A.
When was VERACYTE, INC.'s most recent earnings call?
VERACYTE, INC. (VCYT) held its most recent earnings call on 2026-07-30, covering fiscal Q2 2026.
What sector is VCYT in?
VERACYTE, INC. (VCYT) operates in the Healthcare sector (Diagnostics & Research industry).